Anti Dandruff action of Meera anti Dandruff Powder

Phase 3

Completed

• Conditions: Health Condition 1: L210- Seborrhea capitis

• Registration Number: CTRI/2021/05/033789
• Lead Sponsor: CavinKare Private Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-10-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1.Male and female subjects who are 18 to 45 years of age.

2. Subjectssuffering from Dandruff of scalp

3. Subjects who are committed not to use medicated/non medicated shampoos/soaps (including soaps containing antibacterial/antifungal agents) or any other antidandruff treatment/hair products (including prescription and non-prescription medications such as hair oil, conditioners) for the entire duration of the study.

4. Subject usually using a shampoo 3 times a week and accepting to follow this rate during the whole study period.

5. Subjects not have participated in any other clinical trial during the past 3 months.

Exclusion Criteria

1. Scalp Psoriasis.

2. Subjects who underwent any type of hair procedures within the past 2 weeks or during the study.

3. Subjects with immediate life threatening diseases such as pre-existing cardiovascular, liver or neoplastic disease.

4. Subjects undergoing treatment for immune-compromised conditions/psychiatric illness.

5. Subjects with any other co- morbid conditions like Diabetes that can affect the study outcome.

6. Pregnant or lactating women.

7. Hypersensitivity to any of the components of the test formulation.

8. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in this clinical study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Total Dandruff Severity Score (TDSS) <br/ ><br>2. Changes in the intensity of hair fall over 4 weeks from baseline to final treatment visit using Visual Analogue Scale (VAS) <br/ ><br>3. Global improvement (self-assessment scoring& Photographs) by the subject. <br/ ><br>4. Pull test ââ?¬â?? to evaluate the severity of hair shedding. <br/ ><br>Timepoint: Week 1, 2, 3 and 4

Secondary Outcome Measures

Name	Time	Method
To monitor for any adverse events during the study period and assess quality of lifeTimepoint: Week 1, 2, 3 and 4